Jennifer Doudna’s development of CRISPR-Cas9—a genome engineering technology that allows researchers to edit DNA—with collaborator Emmanuelle Charpentier earned them the 2020 Nobel Prize in Chemistry. Doudna is founder of the Innovative Genomics Institute and the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences at University of California, Berkeley. She is also a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, Gladstone Institutes, National Academy of Sciences, and American Academy of Arts and Sciences. Doudna is a leader in the global public debate on the responsible use of CRISPR and has co-founded and serves on the advisory panel of several companies using the technology in unique ways. She is co-author of "A Crack in Creation," a personal account of her research and the societal and ethical implications of gene editing.
Previously
Barely a dozen years ago, Jennifer Doudna and her colleagues published a paper in Science about CRISPR, the pioneering gene-editing technique that thrilled the scientific comm...
History was made this year when the first FDA-approved CRISPR-based gene editing therapy became available to patients, designed to cure sickle cell anemia. That represents gr...
Not since the atomic bomb has a technology so alarmed its inventors that they warned the world about its use. Not, that is, until the spring of 2015, when biologist Jennifer D...